Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GALVmed receives aid to develop vaccine projects for Africa

GALVmed will receive $10 million in UK government aid to advance vaccine projects in Africa.

GALVmed will use the funds from the government's Department for International Development (DFID) to develop seven new vaccines for neglected tropical diseases.

The funding for GALVmed will enable the charity to focus on R&D work for combination vaccines, by addressing diseases affecting large ruminants, small ruminants and poultry.

This funding is part of joint funding with the Bill & Melinda Gates Foundation, who awarded GALVmed $40m earlier this year. The Gates Foundation and DFID are long-term backers of GALVmed.

GALVmed told Animal Pharm the seven vaccines supported by this latest funding include:

  • Small ruminant systemic multivalent vaccine;

  • Small ruminant reproductive multivalent vaccine;

  • Peste des petits ruminants-sheep and goat pox combination vaccine for Asia;

  • Contagious bovine pleuropneumonia -lumpy skin disease +/- Rift Valley fever combination vaccine;

  • Newcastle disease combination vaccine;

  • Peste des petits ruminants marker vaccine; and

  • African swine fever vaccine.

Edinburgh-based GALVmed will also be working on the Brucellosis Vaccine Prize and on a trypanosomosis program, which has separate funding.  

Topics

What to read next

UsernamePublicRestriction

Register

PS142304

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel